

Indian Active Pharmaceutical Ingredients (APIs) Industry Report, 2008-2009



India plays an important part in the global API market. The API output value of India was US \$4.1 billion in 2007, with the CAGR as high as 18.81% during 2003-2007. And Indian ranks at the fourth in the world in terms of API output.

India currently has about 3000 API factories and 5,000 reagent factories, the key API producers including the Ranbaxy, Dr. Reddy, Cipla Ltd, Cadila Healthcare and Matrix. They are producing more than 400 sorts of API and around 10,000 kinds of reagents, satisfying over 90% of Indian domestic demand.

The pharmaceutical companies such as Dr.Reddy, Wockhardt and Sun Pharmaceuticals are also producing API. In the FY2007, 40% sales of Dr. Reddy were contributed by the API. Similarly, 19% revenues of Wockhardt and 18% revenues of Sun Pharmaceuticals were contributed by the API respectively.

Top Ten API Producers in India, 2007

<i>Producer</i>	<i>Revenue</i>	<i>Net Profit</i>	<i>Assets</i>
Ranbaxy	1885.36	196.64	2388.58
Dr. Reddy	1319.12	111.24	1958.89
Cipla Ltd	1104.38	177.99	1455.50
Sun Pharmaceuticals	889.07	377.52	1559.81
Lupin	739.56	103.65	855.56
Piramal Healthcare	730.96	84.75	637.54
Wockhardt	676.44	97.96	1308.37
Aurobindo Pharma	642.40	60.55	922.79
Cadila Healthcare	590.42	64.47	646.89
Glenmark Pharmaceuticals	521.77	160.50	747.88

Source: ResearchInChina

The API export of India will enjoy a rapid growth in the coming years, According to the Tata Strategic Management Group, Indian API export value will increase to US \$12.75 billion in 2012 from US \$3.75 billion in 2007.

This report gives an in-depth analysis of 28 Indian API Producers, including their profile, operating revenues, net profit, products, market distribution and future developments etc.

Table of Contents

- **1. Overview of API Industry in India**
- 1.1 Introduction to API
- 1.2 Status Quo and Prospects of Indian API Industry

- **2. Analysis on Major API producers in India**
- 2.1 Alembic Ltd
- 2.2 Atul Ltd
- 2.3 Aurobindo Pharma Ltd
- 2.4 Cadila Healthcare Ltd
- 2.5 Cipla Ltd
- 2.6 Dr. Reddy's Laboratories Limited
- 2.7 Dishman Pharmaceuticals & Chemicals Ltd
- 2.8 Divi's Laboratories Ltd
- 2.9 Elder Pharmaceuticals Ltd
- 2.10 FDC Ltd
- 2.11 Glenmark Pharmaceuticals Ltd
- 2.12 Hikal Ltd
- 2.13 Ind Swift Laboratories Ltd
- 2.14 IPCA Laboratories Ltd
- 2.15 JB Chemicals & Pharmaceuticals Ltd
- 2.16 Lupin Ltd
- 2.17 Matrix Laboratories Ltd
- 2.18 Merck Ltd
- 2.19 Orchid Chemicals & Pharmaceuticals Ltd
- 2.20 Pfizer Ltd
- 2.21 Piramal Healthcare Ltd
- 2.22 Ranbaxy Laboratories Ltd
- 2.23 Shasun Chemicals and Drugs Ltd
- 2.24 Sterling Biotech Ltd
- 2.25 Sun Pharmaceuticals Industries Ltd
- 2.26 Torrent Pharmaceuticals Ltd
- 2.27 Unichem Laboratories Ltd
- 2.28 Wockhardt Ltd

Selected Charts

- Global API Manufacturing 2007
- Top 10 API producers in India, 2007
- Revenue and net profit of Alembic, 2003-2007
- Financial highlight of Alembic, 2007-2008
- Number of new products launched by Alembic, 2007-2008
- Key products of animal-health of Alembic
- Revenue and net profit of Atul, 2003-2007
- Market position of Pharmaceuticals and Intermediates Department of Atul
- Revenue and net profit of Aurobindo, 2004-2008
- financial Performance of Aurobindo,2006-2008
- Sales of different drugs of Aurobindo
- the operational statement of Aurobindo as at March 31,2008(by region)
- Revenue and net profit of Cadila, 2004-2008
- Strong brand of Cadila
- Global operations of Zydus Cadila
- Revenue break-up of Cadila
- Research focus of Cadila
- Strategies for growth momentum of Cadila
- Scheme of Cadila for 2009
- Revenue and net profit of Cipla, 2004-2008
- Revenue and net profit of Dr. Reddy, 2003-2007
- Revenue from Key API Products of Dr. Reddy, 2006-2008
- Consolidated Business-Wise Performance of Dr. Reddy

- Geographic Mix of APIs of Dr. Reddy, 2007-2008
- Revenue and net profit of Dishman, 2003-2007
- Revenue and net profit of Divis, 2004-2008
- Revenue and net profit of Elder, 2004 -2008
- Products of Elder
- Financial Performance of Elder, FY2006-08
- Stocks and sales of finished goods of Elder
- Revenue and assets of Elder, 2007-2008
- Revenue and net profit of FDC, 2004-2008
- Revenue and assets of FDC
- Revenue and net profit of Glenmark, 2004-2008
- Financial Performance of Glenmark
- Production Lines & Regulatory Approvals of API of Glenmark
- Four main business of Glenmark
- Growth plans and targets for Glenmark
- Key milestones planned for 2008-2010 of Glenmark
- Revenue and net profit of Hikal, 2004-2008
- Regulatory filing status of current Products of Hikal
- Development of pharma pipeline of Hikal, 1997-2005
- Operational statement of Hikal
- Revenue and net profit of Ind Swift, 2004-2008
- Shareholding pattern of Ind Swift as on March 31, 2008
- Composition of export income of Ind Swift
- Operating Expenses break-up of Ind Swift
- Expenditure of R&D of Ind Swift
- Revenue and net profit of IPCA, 2004-2008

- Distribution of Shareholding of IPCA as on March 31,2008
- Break-up of pharmaceutical sales of IPCA
- Domestic branded formulations groupwise contribution for 2007-08 of IPCA
- Continentwise exports of IPCA
- Financial highlights of IPCA from 1998 to 2008
- Revenue and net profit of JBCPL, 2004 - 2008
- JBCPL Composition of Sales (Formulations & APIs)
- JBCPL Composition of Sales (Formulations & APIs)
- Revenue and net profit of Lupin, 2004-2008
- Products of Lupin, 2008
- Facilities of Lupin, 2008
- Products Coverage of Lupin, 2008
- Business model of Lupin, 2008
- Sales growth and revenue composition of Lupin, 2007-2008
- Lupin Consolidated Gross Sales by Market, 2004-2008
- Lupin Consolidated Gross Sales by product, 2004-2008
- Revenue Composition of Lupin in FY2007-08
- Lupin Revenue of Exports by Product, 2004-2008
- API Sales of Lupin in FY2007-08
- API Key Markets
- Strategy of Lupin, 2008
- Revenue and Net Profit of Matrix, 2004-2008
- Capacities and production of Matrix, 2006-2007
- Three principal products of Matrix, 2007
- Shareholding pattern of Matrix, 2008
- Product group-wise performance of Matrix

- Revenue and Net Profit of Merck, 2004-2008
- Pharmaceuticals products of Merck launched during 2008
- Operational Performance of Merck, 2007-2008
- Revenue and net profit of Orchid, 2004-2008
- Products of Orchid ,2008
- Product range of Orchid,2008
- Global market reach of Orchid, 2008
- Orchid product development pipeline
- Revenue and Net Profit of Pfizer, 2004-2008
- Brands holding by Piramal,2009
- Drug life-cycle of Piramal,2009
- Global outsourcing partner,2009
- Strategy of Piramal,2009
- Revenue and net profit of Ranbaxy,2003-2007
- Business model of Ranbaxy,2007
- Global operation of Ranbaxy,2007
- Europe-Key Markets of Ranbaxy,2007
- Emerging markets of Ranbaxy,2007
- Geographic sales split of Ranbaxy, 2007
- Inorganic strategy of Ranbaxy,2007
- Aspirations of Ranbaxy (2012)
- Revenue and net profit of SCDL,2004 - 2008
- Revenue and net profit of Sterling,2004 - 2008
- Products structure of Sun Pharmaceuticals,2009
- Revenue composition of Sun Pharmaceuticals,2009

- Growing revenue of Sun Pharmaceuticals,2003-2007
- Sustained profitability of Sun Pharmaceuticals,2003-2007
- Successful acquisitions of Sun Pharmaceuticals,1995-2003
- Peer comparison of Sun Pharmaceuticals,1992-2007
- Strategy and approach of Sun Pharmaceuticals,2009
- Revenue and net profit of Torrent, 2004-2008
- Information in case of imported technology,2005-2007
- Sales of Torrent Pharmaceuticals by regions,2006-2008
- Revenue and net profit of Unichem,2004-2008
- Comparison of power brands of Unichem,2006-2008
- Shareholding pattern as on March 31, 2008
- Financial highlights of Unichem,2005-2008
- Revenue and net profit of Wockhardt,2003-2007
- Biopharmaceuticals value chain of Wockhardt,2008
- Sales Revenues and Profits of Wockhardt,1992-2007
- Global operations of Wockhardt,2008
- Operation transformation of Wockhardt in 1992, 2000 and 2007
- Balanced portfolio of Wockhardt,2008
- Eight acquisitions of Wockhardt,1997-2007

How to Buy

Product details			How to Order
Single user	USD	File	By email: report@researchinchina.com
	999	PDF	By fax: 86-10-82600829
	1,499	PDF	By online: www.researchinchina.com
Publication date: Apr. 2009			
For more information, call our office in Beijing, China:			
Tel: 86-10-82600828			
Website: www.researchinchina.com			